URL Pharma Sues Par (PRX); Alleges Infringement of Colcrys Patents
Tweet
Share
E-mailGet Alerts PRX Hot Sheet
Join SI Premium – FREE
Shares of Par Pharma (NYSE: PRX) do not seem to be responding to a Bloomberg headline which says URL Pharma has sued the company over its generic gout treatment. URL has alleged Par's drug infringes on colcrys patents.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Quantum Cyber rejects short-seller's offer to halt reports if lawsuit dropped
- Software M&A heats up: Which SaaS stocks could be next for private equity?
- ABAT posts record gross profit, wins reinstatement of $57M DOE grant
Create E-mail Alert Related Categories
Litigation, RumorsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
